Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Chief Medical Officer and SVP | February 28, 2019 | March 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date February 28, 2019 · Filed March 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,183 |
Ending reported balance
After 2019-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-03-01 · Exercise / conversion · Acquired 16,269 · Balance 221,006 F1: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. Row 2 · 2019-03-01 · Tax withholding · Disposed 4,823 · Balance 216,183 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2029-02-28 | Direct | 67,400 |
Reported balance
After 2019-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-28 · Grant · Acquired 67,400 · Balance 67,400 F2: The option vests in three approximately equal annual installments beginning on February 28, 2020. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-01 · Exercise / conversion · Disposed 16,269 · Balance 0 F1: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vested in three equal annual installments beginning on the anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis.
F2: The option vests in three approximately equal annual installments beginning on February 28, 2020.
F3: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vested in three equal annual installments beginning on the anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2019 Filed Mar 5, 2019 02:09 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 16,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-19-000184 · stromatt.xml · derivative · entry 4 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,269 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vested in three equal annual installments beginning on the anniversary of the grant date. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vested in three equal annual installments beginning on the anniversary of the grant date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:09 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 4,823 | $1.57 | $7,572.11 |
DisclosureSEC source: 0001019056-19-000184 · stromatt.xml · nonDerivative · entry 2 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,183 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:09 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 16,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-19-000184 · stromatt.xml · nonDerivative · entry 1 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 02:09 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 67,400 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000184 · stromatt.xml · derivative · entry 3 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2029-02-28 F2 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 13,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-18-000439 · stromatt_4.xml · derivative · entry 3 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,269 Underlying: Common Stock · 13,892 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 9, 2018. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 9, 2018. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Options (Right to Buy) · Derivative | 67,400 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001019056-18-000439 · stromatt_4.xml · derivative · entry 2 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2028-03-09 F2 · derivative.exercise_date: On March 9, 2018, the reporting person was granted 67,400 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 13,892 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-18-000439 · stromatt_4.xml · nonDerivative · entry 1 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 16,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-18-000416 · stromatt_4.xml · derivative · entry 2 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,161 Underlying: Common Stock · 16,269 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments on the anniversary of the grant date. F2 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments on the anniversary of the grant date. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 16,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-18-000416 · stromatt_4.xml · nonDerivative · entry 1 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| February 03, 2018 Filed Feb 7, 2018 00:23 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 27,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-18-000291 · stromatt_4.xml · derivative · entry 2 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,430 Underlying: Common Stock · 27,381 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 3, 2016, the reporting person was granted 54,762 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. F2 · derivative.expiration_date: On August 3, 2016, the reporting person was granted 54,762 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. Read SEC document |
| February 03, 2018 Filed Feb 7, 2018 00:23 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 27,381 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-18-000291 · stromatt_4.xml · nonDerivative · entry 1 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:00 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 78,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000649 · stromatt_4.xml · derivative · entry 2 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,811 Underlying: Common Stock · 78,123 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs were issued on August 3, 2016 and fully vested on August 1, 2017. F2 · derivative.expiration_date: The RSUs were issued on August 3, 2016 and fully vested on August 1, 2017. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:00 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 78,123 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000649 · stromatt_4.xml · nonDerivative · entry 1 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 01:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Option (right to buy) · Derivative | 33,700 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001019056-17-000550 · stromatt_4.xml · derivative · entry 1 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,700 Underlying: Common Stock · 33,700 shares Expires 2027-05-31 F1 · date: The option grant was approved by a committee of Aptevo Therapeutics Inc.'s board of directors on February 22, 2017, subject to stockholder approval of the Amended and Restated 2016 Stock Incentive Plan (the "Plan") under which the option was granted. Aptevo Therapeutics Inc.'s stockholders approved the Plan on May 31, 2017. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 1, 2018. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 24,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000286 · stromatt_4.xml · derivative · entry 9 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,934 Underlying: Common Stock · 24,836 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F4 · derivative.exercise_date: The RSUs were originally issued by Emergent on March 11, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on March 10, 2017. F4 · derivative.expiration_date: The RSUs were originally issued by Emergent on March 11, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on March 10, 2017. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 6,570 | $1.78 | $11,694.60 |
DisclosureSEC source: 0001019056-17-000286 · stromatt_4.xml · nonDerivative · entry 6 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,072 Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 24,836 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000286 · stromatt_4.xml · nonDerivative · entry 5 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 09, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 13,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000286 · stromatt_4.xml · derivative · entry 8 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,770 Underlying: Common Stock · 13,902 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent on March 10, 2015 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs vest as follows: 13,902 on March 9, 2017 and 13,892 on March 9, 2018. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent on March 10, 2015 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs vest as follows: 13,902 on March 9, 2017 and 13,892 on March 9, 2018. Read SEC document |
| March 09, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 3,678 | $1.80 | $6,620.40 |
DisclosureSEC source: 0001019056-17-000286 · stromatt_4.xml · nonDerivative · entry 4 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,806 Read SEC document |
| March 09, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 13,902 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000286 · stromatt_4.xml · nonDerivative · entry 3 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 01, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 16,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000286 · stromatt_4.xml · derivative · entry 7 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,672 Underlying: Common Stock · 16,269 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments on the anniversary of the grant date. F2 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments on the anniversary of the grant date. Read SEC document |
| March 01, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 5,312 | $2.02 | $10,730.24 |
DisclosureSEC source: 0001019056-17-000286 · stromatt_4.xml · nonDerivative · entry 2 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,582 Read SEC document |
| March 01, 2017 Filed Mar 14, 2017 01:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 16,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000286 · stromatt_4.xml · nonDerivative · entry 1 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 33,700 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001019056-17-000238 · stromatt_4.xml · derivative · entry 1 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,580 Underlying: Common Stock · 33,700 shares Expires 2027-02-24 F1 · derivative.exercise_date: The options vest in three equal annual installments beginning on February 24, 2018. Read SEC document |
| February 03, 2017 Filed Feb 8, 2017 23:31 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 27,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000113 · stromatt_4.xml · derivative · entry 2 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,941 Underlying: Common Stock · 27,381 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 3, 2016, the reporting person was granted 54,762 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. F2 · derivative.expiration_date: On August 3, 2016, the reporting person was granted 54,762 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. Read SEC document |
| February 03, 2017 Filed Feb 8, 2017 23:31 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 27,381 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000113 · stromatt_4.xml · nonDerivative · entry 1 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| August 03, 2016 Filed Sep 27, 2016 19:43 UTC Amendment | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 78,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-16-001559 · stromatt_4a.xml · derivative · entry 3 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,322 Underlying: Common Stock · 78,123 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents the right of the reporting person to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: This report has been amended to reflect that the RSUs will vest on August 1, 2017. F4 · derivative.expiration_date: This report has been amended to reflect that the RSUs will vest on August 1, 2017. F5 · balance_after: This report has been amended to reflect the 101,437 RSUs that were originally issued by Emergent and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed by the Issuer under its Converted Equity Awards Incentive Plan. Read SEC document |
| August 03, 2016 Filed Sep 27, 2016 19:43 UTC Amendment | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 54,762 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-16-001559 · stromatt_4a.xml · derivative · entry 2 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,762 Underlying: Common Stock · 54,762 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents the right of the reporting person to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: This report has been amended to reflect that the RSUs will vest in two equal installments on February 3, 2017 and February 3, 2018. F3 · derivative.expiration_date: This report has been amended to reflect that the RSUs will vest in two equal installments on February 3, 2017 and February 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.